Design of a trans protease lentiviral packaging system that produces high titer virus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The structural and enzymatic proteins of the human immunodeficiency virus (HIV) are initially generated as two long polyproteins encoded from overlapping reading frames, one producing the structural proteins (Gag) and the second producing both structural and enzymatic proteins (Gag-Pol). The Gag to Gag-Pol ratio is critical for the proper assembly and maturation of viral particles. To minimize the risk of producing a replication competent lentivirus (RCL), we developed a "super-split" lentiviral packaging system in which Gag was separated from Pol with minimal loss of transducibility by supplying protease (PR) in trans independently of both Gag and Pol. RESULTS: In developing this "super-split" packaging system, we incorporated several new safety features that include removing the Gag/Gag-Pol frameshift, splitting the Gag, PR, and reverse transcriptase/integrase (RT/IN) functions onto separate plasmids, and greatly reducing the nucleotide sequence overlap between vector and Gag and between Gag and Pol. As part of the construction of this novel system, we used a truncated form of the accessory protein Vpr, which binds the P6 region of Gag, as a vehicle to deliver both PR and RT/IN as fusion proteins to the site of viral assembly and budding. We also replaced wt PR with a slightly less active T26S PR mutant in an effort to prevent premature processing and cytoxicity associated with wt PR. This novel "super-split" packaging system yielded lentiviral titers comparable to those generated by conventional lentiviral packaging where Gag-Pol is supplied intact (1.0 x 106 TU/ml, unconcentrated). CONCLUSION: Here, we were able to create a true "split-function" lentiviral packaging system that has the potential to be used for gene therapy applications. This novel system incorporates many new safety features while maintaining high titers. In addition, because PR is supplied in trans, this unique system may also provide opportunities to examine viral protein processing and maturation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“In the case of lentiviruses, which are more complex, it was found that not only can the Gag-Pol be separated from the vector and envelope, but that the accessory proteins (Vif, Vpr, Vpu, and Nef) and regulatory proteins (Rev and Tat) could also be either eliminated or supplied in trans [19-21].”
BackgroundCharacterization of ribosomal frameshifting in HIV-1 gag-pol expression
Jacks, T., Power, M. D., Masiarz, F. R., Luciw, P. A., Barr, P. J., & Varmus, H. E. (1988) · Nature · doi:10.1038/331280a0 · Cited by 966
Park, J., & Morrow, C. D. (1991) · Journal of Virology · doi:10.1128/jvi.65.9.5111-5117.1991 · Cited by 163 · cited 1×
“In addition, the expression of Gag without Gag-Pol has been shown to result in the assembly of particles that are noninfectious [7], and in the reverse case, when Gag-Pol is expressed without Gag, there is efficient PR processing but no production of virions [8].”
BackgroundDevelopment of a Novel Trans-Lentiviral Vector That Affords Predictable Safety
Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., & Kappes, J. C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0095 · Cited by 137 · cited 3×
“Vpr has also been used to supply RT/IN as part of a safer lentiviral packaging system in which GagPR and RT/IN functions were delivered by separate plasmids [29].”
BackgroundMethodInfluential
Cited by
Rejuvenation of the muscle stem cell population restores strength to injured aged muscles
Cosgrove, B. D., Gilbert, P. M., Porpiglia, E., Mourkioti, F., Lee, S. P., Corbel, S. Y., Llewellyn, M. E., Delp, S. L., & Blau, H. M. (2014) · Nature Medicine · doi:10.1038/nm.3464 · Cited by 677
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationShort Telomeres and Stem Cell Exhaustion Model Duchenne Muscular Dystrophy in mdx/mTR Mice
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp, S., Pomerantz, J. H., Artandi, S. E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.11.039 · Cited by 512
Bar, E. E., Lin, A., Mahairaki, V., Matsui, W., & Eberhart, C. G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091021 · Cited by 373
State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 106
Metadata
- Authors
- Westerman, K. A., Ao, Z., Cohen, É. A., & Leboulch, P.
- Venue
- Retrovirology
- Published
- 2007
- Volume
- 4
- Issue
- 1
- Pages
- 96
- ISSN
- 1742-4690 (ISSN-L)
- OpenAlex
- W2101412271
- Cited by
- 33
- References
- 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of a trans protease lentiviral packaging system that produces high titer virus. https://app.cochat.ai/papers/10.1186/1742-4690-4-96
- The paper
- Westerman, K. A., Ao, Z., Cohen, É. A., & Leboulch, P. (2007). Design of a trans protease lentiviral packaging system that produces high titer virus. Retrovirology. https://doi.org/10.1186/1742-4690-4-96
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.